Search filters

List of works by Hadas Dvory-Sobol

Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells

scientific article published on September 2005

Celecoxib but not rofecoxib inhibits the growth of transformed cells in vitro

scientific article published on January 2004

Celecoxib leads to G2/M arrest by induction of p21 and down-regulation of cyclin B1 expression in a p53-independent manner

scientific journal article

Characterization of Resistance to the Protease Inhibitor GS-9451 in Hepatitis C Virus-Infected Patients ⬇️

scientific article published on August 6, 2012

Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein

scientific article published on 27 June 2016

Clinical and in vitro resistance to GS-9669, a thumb site II nonnucleoside inhibitor of the hepatitis C virus NS5B polymerase

scientific article

Cyclooxygenase-2 as target for chemopreventive interventions: new approaches.

scientific article published on January 2007

Development and application of a fast, reproducible assay to measure HCV NS3 protease activity using Escherichia coli lysate

scientific article published on 18 September 2015

Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials

scientific article published on 5 April 2017

Efficacy of Sofosbuvir Plus Ribavirin in Veterans With Hepatitis C Virus Genotype 2 Infection, Compensated Cirrhosis, and Multiple Comorbidities

scientific article published on 26 May 2016

Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial

scientific article published on 30 July 2016

Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial

scientific article published on 30 July 2016

Gene therapy approach in prostate cancer cells using an active Wnt signal

scientific article

Identification of a class of HCV inhibitors directed against the nonstructural protein NS4B.

scientific article published on January 2010

In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir

scientific article published on 11 January 2016

In vitro selection of resistance to sofosbuvir in HCV replicons of genotype-1 to -6.

scientific article published on March 2017

Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials.

scientific article published on 28 September 2014

L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions.

scientific article

Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease

scientific article published on 15 May 2015

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.

scientific article published on 21 July 2015

Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis

scientific article published on 9 May 2015

Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial

scientific article

Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial

scientific article published on March 2017

Ledipasvir/sofosbuvir-based treatment of patients with chronic genotype-1 HCV infection and cirrhosis: results from two Phase II studies.

scientific article

Long-term persistence of HCV NS5A resistance associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir

scientific article

MF tricyclic and sulindac retard tumor formation in an animal model

scientific article published in January 2006

Malignant transformation of normal enterocytes following downregulation of Bak expression

scientific journal article

Mechanism of an amphipathic alpha-helical peptide's antiviral activity involves size-dependent virus particle lysis

scientific article published in December 2009

NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome

scientific article published on 17 January 2017

Perioperative Ledipasvir-Sofosbuvir for HCV in Liver-Transplant Recipients

scientific article published in November 2016

Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir

scientific article

Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir

scientific article published on 10 June 2016

Resistance Analysis in Patients with Genotype 1-6 HCV Infection Treated with Sofosbuvir/Velpatasvir in the Phase 3 Studies

scientific article published on 5 December 2017

Resistance Characterization of Ledipasvir and Velpatasvir in Hepatitis C Virus Genotype 4.

scientific article published on 6 October 2017

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

scientific article

Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation

scientific article published on 7 October 2014

Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial

scientific article published on 8 September 2014

Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis

scientific article

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial

scientific article published on 15 March 2013

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection

scientific article published on June 2017

Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen

scientific article published on 12 May 2017

Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus

scientific article published on 21 February 2017

Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir

scientific article

Suppression of gastric cancer cell growth by targeting the beta-catenin/T-cell factor pathway

scientific article

The Future of HCV Therapy: NS4B as an Antiviral Target ⬇️

scientific article published on November 10, 2010

Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized Trial

scientific article published on 15 November 2016

Paulina is supported by:

About Paulina

Help